A61P 21 - Drugs for disorders of the muscular or neuromuscular system

Patents for A61P 21 - Drugs for disorders of the muscular or neuromuscular system (23,287)
11/2006
11/23/2006	US20060264434 Chemokine receptor binding heterocyclic compounds
11/23/2006	US20060264363 Inhibition of nerve cell death by inhibiting degradation of shc3, atf6 or crebl1 by htra2 and method of ameliorating neurodegenerative diseases
11/23/2006	US20060263827 Novel endothelial cells, antibodies directed against said cells and use thereof, in particular for screening angiogenesis inhibiting substances
11/23/2006	US20060263447 Treating pulmonary disorders with gaseous agent causing repletion of GSNO
11/23/2006	US20060263407 Deliver platelet rich plasma, sodium bicarbonate, calcium gluconate, choline chloride buffers, thrombin, collagen, epinephrine releasate, via catheter; stent implants
11/23/2006	US20060263388 Injectable or oral administration of a drug with an active ingredient of an extract from inflamed cutaneous tissue of rabbits inoculated with vaccinia virus; side effect reduction
11/23/2006	CA2609102A1 Int6 protein involved in hypoxia stress induction and use thereof
11/23/2006	CA2607472A1 Antipyretic agents against vr1-antagonist-induced increases in body temperature
11/22/2006	EP1724283A2 Corticotropin releasing factor receptor 2 agonists
11/22/2006	EP1724279A2 5-Beta-sapogenin and pseudosapogenin derivatives and their use in the treatment of dementia.
11/22/2006	EP1724267A1 Pyrimidine derivative
11/22/2006	EP1724264A1 Nitriles and medicinal compositions containing the same as the active ingredient
11/22/2006	EP1722798A1 Pyrimidine compounds as purine receptor antagonist
11/22/2006	EP1173465B1 Novel human voltage-gated potassium channel
11/22/2006	EP0935415B1 In vitro methods for delivering nucleic acids into a cell
11/22/2006	CN1864667A A stable lyophilized preparation of rocuronium bromide and preparation method thereof
11/22/2006	CN1285572C Cannabinod receptor ligands
11/21/2006	US7138543 Thiolalkyl benzoic acid derivatives
11/21/2006	US7138530 for inhibiting the enzyme C1s, a protease in the classical pathway of the complement system; and the use of this inhibition to treat or ameliorate acute or chronic disorders in mammals
11/21/2006	US7138499 antibody that binds to a peptide of given amino acid sequence related to the sulfotransferase drug-metabolizing enzyme subfamily
11/21/2006	US7138427 Cognition activators
11/21/2006	US7138424 Indole derivatives, method for preparing same and pharmaceutical compositions containing same
11/21/2006	US7138413 Administering tertiary amines, e.g., 3,3-Dimethylbutyl 3-piperidinopropyl ether, 3-Phenylpropyl 3-piperidinopropyl ether, or3-(4-Chlorophenyl)propyl 3-piperidinopropyl ether to treat cognitive disorders such as attention, wakefulness and memory disorders
11/21/2006	US7138404 Anxiolytic agents and analgesics
11/21/2006	US7138148 Use of extracts of Ginkgo biloba for preparing a medicament intended to treat sarcopenia
11/21/2006	CA2478621C Botulinum toxin pharmaceutical compositions
11/19/2006	CA2556536A1 Method of increasing intracellular concentrations of phosphate and increasing the force of muscular contractions
11/16/2006	WO2006119965A2 Growth factor mutants with altered biological attributes
11/16/2006	WO2004108157A8 Use of myostatin (gdf8) inhibitors in conjunction with corticosteroids for treating neuromuscular disorders
11/16/2006	WO2002094236A9 Delivery of antipsychotics through an inhalation route
11/16/2006	US20060258839 Cardiovascular disorders; antiinflammatory agents; resemble a G amphipathic helix of apolipoprotein J; phospholipids
11/16/2006	US20060258598 Alpha-keto carbonyl calpain inhibitors
11/16/2006	US20060258003 Culture medium composition, culture method, and myoblasts obtained, and their uses
11/16/2006	US20060257911 Of given nucleotide sequence; diagnosis, treatment, and prevention of cell proliferative, neurological, cardiovascular, gastrointestinal, autoimmune/inflammatory, and metabolic disorders
11/16/2006	US20060257882 Novel polynuceotides and polypeptides encoded thereby
11/16/2006	US20060257427 Molecule (antibody, peptide or chemical), coupled to a detectable label, cytotoxic agent or solid support, that specifically binds an extracellular portion of the latent viral membrane bound protein of Epstein-Barr Virus expressed in the latent viral membrane in the latent life cycle
11/16/2006	US20060257329 Delivery of drug esters through an inhalation route
11/15/2006	EP1720553A1 Pyrimidine compounds as purine receptor antagonist
11/15/2006	EP1720552A2 Methods for treating inflammatory and autoimmune diseases
11/15/2006	EP1423121B1 Cysteine protease inhibitors with 2-cyano-4-amino-pyrimidine structure and cathepsin k inhibitory activity for the treatment of inflammations and other diseases
11/15/2006	EP1414443B1 BENZIMIDAZO 4,5-f\|ISOQUINOLINONE DERIVATIVES
11/15/2006	CN1863811A Stable vitamin B6 derivative
11/15/2006	CN1284851C Somatic cell derived embryonic stem cell and its differentiated cell
11/15/2006	CA2556802A1 Increasing atp availability by inhibition of creatine kinase (ck) leakage resulting from high-intensity exercise
11/14/2006	US7135600 Selective beta 2-adrenoreceptor agonists; rapid onset of action, long duration; such as 3-(4-{[6-{(-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl}amino)hexyl]oxy}butyl)benzenesulfonamide; synthesis
11/14/2006	US7135471 Aryl oximes
11/14/2006	US7135464 Method of administering decitabine
11/14/2006	US7135453 Reagents and methods for smooth muscle therapies
11/14/2006	US7135279 4-alpha glucotransferases; enzymes inhibitors; enantimorphs; adrenergic blocking agents; proteases; superoxide dismutases; carbonic anhydrases
11/09/2006	WO2006118328A1 Degranulation inhibitor
11/09/2006	WO2006118196A1 Dpp4 inhibitor and pharmaceutical application thereof
11/09/2006	WO2006118131A1 Peptide having anti-anxiety effect and method for screening thereof
11/09/2006	US20060252833 Improve efficiency when administered with conventional drugs; side effect reduction; Parkinson's disease therapy; administering a fatty acid
11/09/2006	US20060252799 Benzo (F) insoindol derivatives and their use as EP4 receptor ligands
11/09/2006	US20060251588 Delivery of erectile dysfunction drugs through an inhalation route
11/09/2006	US20060251587 Delivery of analgesics through an inhalation route
11/09/2006	CA2606162A1 Peptide having antianxiety activity and screening method therefor
11/08/2006	EP1719512A2 Sarsasapogenin and smilagenin for treating cognitive dysfunctions
11/08/2006	EP1337269B1 Association of calpain inhibitors and reactive oxygen species trapping agents
11/08/2006	EP1080074B1 Heterocyclic substituted amides, their production and their use
11/08/2006	CN1859918A Methods for treating acute and overuse sprain and strain using hyaluronic acid
11/08/2006	CN1283793C Chemokine-like factor superfamily having skeletal muscle stimulating activity and immunoregulation function
11/08/2006	CN1283662C Antagonistic anti-hFAS ligand human antibodies and fragments thereof
11/08/2006	CN1283656C C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases
11/07/2006	US7132546 Aniline derivatives or salts thereof and cytokine production inhibitors containing the same
11/07/2006	US7132439 Bis-benzimidazoles and related compounds as potassium channel modulators
11/07/2006	US7132285 Extracorporeal treatment of the patient's blood cells to induce apoptosis and administration of the apoptotic bodies and/or cells to patient; T-cell- mediated and inflammatory disorders
11/07/2006	US7132259 nucleic acids encoding neurotoxin polypeptides with a functional binding domain, translocation domain, a therapeutic domain and a non-native protease cleavage site for cleavage in vitro following expression as a single chain; for biosynthesis of botulinum neurotoxins in host cells
11/07/2006	CA2274093C Substituted pyrimidinone and pyridinone compounds and their use
11/02/2006	WO2006116302A2 High-potency botulinum toxin formulations
11/02/2006	WO2006115448A1 Treatment of inclusion body myositis
11/02/2006	WO2006115188A1 Heterocyclic compound
11/02/2006	WO2006115026A1 Humanin receptor or humanin-like polypeptide receptor
11/02/2006	WO2003072715A3 Gasp1: a follistatin domain containing protein
11/02/2006	US20060247448 zearalenone-like macrolides, used to to inhibit nuclear factor kappa-beta (NF- kappa B) activation, as sucnscreen agents and in the treatment of inflammatory or autoimmune disorders and disorders involving malignancy or increased angiogenesis
11/02/2006	US20060247313 administering to a osteoporosis patient an effective amount of a amino acid formulation containing 10 to 40 parts by weight of L-arginine or L-glutamine; 5 to 20 parts of L-valine; 8 to 30 parts of L-isoleucine; and10 to 35 parts of L-leucine; regeneration of tendon and ligamet; antiaging of skin
11/02/2006	US20060247261 Pyrimidine compounds
11/02/2006	US20060247223 Non-imidazole alkylamines as histamine H3- receptor ligands and their therapeutic applications
11/02/2006	US20060246110 Sustained release pharmaceutical composition
11/02/2006	US20060246085 Methods for manipulating satiety
11/02/2006	US20060246066 Cleavable reagents for specific delivery to disease sites
11/02/2006	US20060246012 Delivery of physiologically active compounds through an inhalation route
11/02/2006	US20060246011 Delivery of diphenhydramine through an inhalation route
11/02/2006	EP1716887A1 Treatment of inclusion body myositis
11/02/2006	EP1716851A1 Thioamides and salts thereof and cytokine production inhibitors containing both
11/02/2006	EP1715888A2 Treatment of abnormalities of the first metatarsophalangeal joint of the foot
11/02/2006	EP1395568B1 4-aminopyrimidine derivatives
11/02/2006	EP1202976B1 Pyrazinones, compositions containing such compounds
11/02/2006	CA2605594A1 Heterocyclic compound
11/01/2006	CN1856308A Excitatory amino acid receptor antagonists
11/01/2006	CN1856301A Curable beta-amino acid
11/01/2006	CN1282636C Vitamin D analogues
10/2006
10/31/2006	US7129243 Respiratory system disorders; cardiovascular disorders; antidiabetic agents; antiarthritic agents; antiinflammatory agents; immunosuppressants
10/31/2006	US7129241 Pyridazine derivatives
10/31/2006	US7129219 enhance humoral and cell-mediated immune responses to vaccine antigens; 2-deoxy-2-amino- beta -D-glucopyranose (glucosamine) glycosidically linked to an cyclic aminoalkyl (aglycon) group
10/31/2006	CA2383599C Methods, kits and compositions for using pyrrole derivatives
10/31/2006	CA2302850C Stretch mask with an adhesive matrix that can be extended at least when wet
10/26/2006	US20060241112 Kinase inhibitors
10/26/2006	US20060241101 Novel benzimidazole derivatives and pharmaceutical compositions comprising these compounds
10/26/2006	US20060241087 Phosphonates useful as modulators of t $g(g)9$g(d)2 lymphocyte activity

1 ... 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 ... 233